Spero Therapeutics Receives $30,000,000 Series A Funding

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=bb31e81b-2f9b-4822-b8c2-d3b200204ea1
Date
6/8/2015
Company Name
Spero Therapeutics
Mailing Address
400 Technology Square 10th Floor Cambridge, MA 20139 USA
Company Description
Spero Therapeutics’ vision is to find, develop, and advance groundbreaking therapeutics to meet critical patient needs in infectious disease using a unique business and drug discovery model. Spero Therapeutics is developing first in class therapeutics for treatment of Gram-negative infections.
Website
http://www.sperotherapeutics.com
Transaction Type
Venture Equity
Transaction Amount
$30,000,000
Transaction Round
Series A
Proceeds Purposes
Spero plans to use the proceeds from this financing to advance the Potentiator franchise into clinical development by 2016, progress its anti-virulence program in partnership with Roche through the submission of an Investigational New Drug (IND) application, and develop additional programs in its pipeline focused on unmet medical needs in bacterial infections.
M&A Terms
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor